Topic,Count,Name,Representation,Representative_Docs
-1,40,-1_rheumatoid arthritis_therapeutic areas_ongoing interest_new treatment,"['rheumatoid arthritis', 'therapeutic areas', 'ongoing interest', 'new treatment', '', '', '', '', '', '']","['As I mentioned earlier, we launched Olumiant in Europe for the treatment of moderate-to-severe rheumatoid arthritis, following European Commission approval earlier this year', 'If the patents are ultimately upheld through all the challenges, they could provide intellectual property protection for Alimta in Japan until June of 2021. To support the increased demand for our products in our pipeline, we announced plans to invest $850 million in our U.S', 'We remain confident the benefit-risk of baricitinib as a new treatment option for adults with moderate-to-severe rheumatoid arthritis, and we will work with the FDA to determine a path forward to ultimately bring baricitinib to patients in the U.S']"
0,25,0_primary endpoint_improved progression_regulatory submissions_free survival,"['primary endpoint', 'improved progression', 'regulatory submissions', 'free survival', 'complete response', 'significant improvement', 'superior efficacy', 'systemic therapy', 'severe plaque', 'next steps']","['Consistent with our prior communications, our expectation remains that regulatory submissions could occur after we have the final overall survival data in 2018. At the American Academy of Dermatology Meeting, we presented Phase 3 data showing that patients with moderate-to-severe plaque psoriasis treated with ixekizumab, or Taltz, demonstrated superior efficacy at 24 weeks compared to patients treated with Stelara', 'On the clinical front, we announced that MONARCH 2 is a Phase 3 trial of abemaciclib in combination with fulvestrant in women with HR+ and HER2- breast cancer met its primary endpoint of improved progression-free survival', ""Finally, we've decided to move the FDA submission of MONARCH 2 from the previously announced timing of Q3 up in to Q2. And just yesterday we announced that the MONARCH 3 study with abemaciclib met its primary endpoint at an interim analysis, demonstrating that women with HR+, HER2- advanced breast cancer who had not received prior systemic therapy experienced a statistically significant improvement in PFS with treatment with abemaciclib plus an aromatase inhibitor compared to placebo plus an aromatase inhibitor""]"
1,20,1_top line_new products_worldwide revenue_strategic objective,"['top line', 'new products', 'worldwide revenue', 'strategic objective', 'total operating', 'pharmaceutical business', 'international inventory', 'interesting combinations', 'gross margin', 'great fit']","['The diversity in our portfolio, our top-line growth prospect and the opportunity for margin expansions over the balance of the decade provide a compelling thesis for investors', 'Right now, under the scenario we see and per the discussion we also had with Derica today, we see a continuous top-line revenue growth driven by new products', 'On our strategic objective of expand margins, our non-GAAP gross margin percent, excluding the effect of FX on international inventory sold, increased by nearly 220 basis points compared to Q1 2016. And total operating expenses as a percent of revenue also declined by nearly 220 basis points']"
2,14,2_key events_financial performance_detailed review_current expectations,"['key events', 'financial performance', 'detailed review', 'current expectations', 'strategic objectives', '', '', '', '', '']","[""I think if we compound that over the next several years, you'll be (51:50) top-tier financial performance out of Lilly"", ""Now let's go to slide five for a more detailed review of the key events that occurred since our last earnings call"", ""Before discussing key events for the quarter, I'll start with a summary of our progress on our strategic objectives since our earnings call in January""]"
